A Conditional Marketing Authorisation (CMA) has been granted in the EU for PAXLOVID™ for the treatment of coronavirus disease 2019 (COVID-19) in adults who do not require supplemental oxygen and who are at increased risk for progressing to severe COVID-19.
View the full Summary of Product Characteristics, which includes dosing, clinical data, and safety information.
View the Package Leaflet, which contains important information for the patient about how to take PAXLOVID™ and what to expect from treatment.
Authentic PAXLOVID™ from Pfizer will include the Pfizer name on the outer carton and will be packaged in 5 aluminium push-through blister cards. To ensure that the tablets are legitimate, look for specific text debossed on each side of the tablets. PF-07321332 tablets are pink, oval-shaped and debossed with ‘PFE’ on one side and ‘3CL’ on the other side. Ritonavir tablets are white to off white, capsule shaped, and debossed with ‘H’ on one side and ‘R9’ on the other side.
The outer carton has a colourless, glossy coating that contains a repeated pattern of the Pfizer name and logo all over. The Pfizer name and logo appear in a contrasting matte finish.
The flaps at each end of the carton are glued as a tamper evident feature of the packaging.
If you suspect the PAXLOVID™ you have received may be counterfeit, please report it to your local representative via 1800 633 363.
This site is intended only for Irish healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.
Copyright © 2022 Pfizer Inc.
Pfizer Healthcare Ireland, 9 Riverwalk, National Digital Park, Citywest Business Campus, Dublin 24, Ireland. Registered in the Republic of Ireland No. 127002.
These pages are not intended for patients or for members of the general public.
I confirm that I am a healthcare professional resident in Ireland
If you select 'No', you will be redirected to covid19oralrx.com where you will be able to access reference information on PAXLOVID™ (PF-07321332; ritonavir)
Update to Interaction Table. Please see section 4.5 of Summary of Product Characteristics and refer to Analgesics section in Table 1